After Recent CRL, scPharmaceuticals Is Trading Below Cash [Seeking Alpha]
scPharmaceuticals Inc. (SCPH)
Last scpharmaceuticals inc. earnings: 3/24 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
scpharmaceuticals.com
Company Research
Source: Seeking Alpha
Summary Just over a month ago, ScPharmaceuticals ( SCPH ) received a CRL for its lead drug candidate Furoscix , a subcutaneous form of furosemide delivered by SCPH's innovative sc2Wear Infusor. Furosemide is a diuretic already commonly used for the management of decompensated heart failure (DHF); typically, furosemide is administered via IV with oral maintenance doses throughout the day. SCPH's sc2Wear Infusor - a wearable device which provides subcutaneous furosemide over a 5-hour period - aims to increase ease of DHF care by providing patients with an option for at-home treatment and removing the existing burden of having to go to the hospital to receive IV treatment. Clinical trials have demonstrated bioequivalence of Furoscix and IV furosemide (current standard of care), and 82% of patients described the device as very comfortable or moderately comfortable. Had it been approved, Furoscix would arguably have represented a significant improvement in the field of DHF car
Show less
Read more
Impact Snapshot
Event Time:
SCPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SCPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SCPH alerts
High impacting scPharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
SCPH
News
- scPharmaceuticals Inc. (NASDAQ: SCPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.MarketBeat
- scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateGlobeNewswire
- scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024GlobeNewswire
- scPharmaceuticals to Participate in Two Upcoming Investor ConferencesGlobeNewswire
SCPH
Earnings
- 3/13/24 - Beat
SCPH
Analyst Actions
- 3/18/24 - HC Wainwright
SCPH
Sec Filings
- 4/12/24 - Form PRE
- 4/5/24 - Form SC
- 4/2/24 - Form 4
- SCPH's page on the SEC website